Literature DB >> 33462741

Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism.

Shivraj Grewal1, Andin Fosam1, Liam Chalk1, Arjun Deven1, Mari Suzuki1, Ricardo Rafael Correa2, Jenny E Blau1, Andrew Paul Demidowich2, Constantine A Stratakis2, Ranganath Muniyappa3.   

Abstract

BACKGROUND: Primary aldosteronism (PA) is associated with an increased risk for dysglycemia. However, the effects of hyperaldosteronism on insulin sensitivity and β-cell function are unclear.
METHODS: Using a cross-sectional study design, we assessed insulin sensitivity and pancreatic β-cell function from an oral glucose tolerance test (OGTT) in patients from two cohorts: subjects with PA (n = 21) and essential hypertension control (EHC) subjects (n = 22). Age, sex, BMI, and mean arterial pressure adjusted measures of insulin sensitivity and β-cell function were compared between the groups.
RESULTS: PA individuals were less insulin sensitive compared to EHC subjects (Quantitative insulin sensitivity check index [QUICKI]: 0.340 ± 0.006 vs. 0.374 ± 0.013, p < 0.001; Matsuda index: 4.14 ± 0.49 vs. 7.87 ± 1.42, p < 0.001; SI: 11.45 ± 4.85 vs. 21.23 ± 6.11 dL/kg/min per μU/mL, p = 0.02). The hepatic insulin resistance index (HIRI) was higher in PA subjects (PA: 5.61 ± 1.01 vs. EHC: 4.13 ± 0.61, p = 0.002). The insulinogenic index (IGI), an index of β-cell function was higher in the PA cohort (PA: 1.49 ± 0.27 vs. 1.11 ± 0.21 μU/mL/mg/dL, p = 0.03). However, the oral disposition index (DI) was similar between the groups (PA: 4.77 ± 0.73 vs. EHC: 5.46 ± 0.85, p = 0.42), which likely accounts for the similar glucose tolerance between the two cohorts, despite lower sensitivity.
CONCLUSIONS: In summary, insulin sensitivity is significantly lower in PA with an appropriately compensated β-cell function. These results suggest that excess aldosterone and/or other steroids in the context of PA may negatively affect insulin action without adversely impacting β-cell function.

Entities:  

Keywords:  Essential hypertension; Insulin sensitivity; Primary aldosteronism; β-cell function

Mesh:

Substances:

Year:  2021        PMID: 33462741      PMCID: PMC8087621          DOI: 10.1007/s12020-020-02576-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  49 in total

1.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.

Authors:  Francesco Fallo; Franco Veglio; Chiara Bertello; Nicoletta Sonino; Paolo Della Mea; Mario Ermani; Franco Rabbia; Giovanni Federspil; Paolo Mulatero
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

2.  Hypertension, the potassium ion and impaired carbohydrate tolerance.

Authors:  J W Conn
Journal:  N Engl J Med       Date:  1965-11-18       Impact factor: 91.245

3.  Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.

Authors:  Gilberta Giacchetti; Vanessa Ronconi; Federica Turchi; Laura Agostinelli; Franco Mantero; Silvia Rilli; Marco Boscaro
Journal:  J Hypertens       Date:  2007-01       Impact factor: 4.844

4.  Insulin sensitivity in patients with primary aldosteronism: a follow-up study.

Authors:  Cristiana Catena; Roberta Lapenna; Sara Baroselli; Elisa Nadalini; Gianluca Colussi; Marileda Novello; Grazia Favret; Alessandra Melis; Alessandro Cavarape; Leonardo A Sechi
Journal:  J Clin Endocrinol Metab       Date:  2006-07-05       Impact factor: 5.958

Review 5.  Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.

Authors:  Gregory L Hundemer
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

Review 6.  Evaluation and Management of Primary Hyperaldosteronism.

Authors:  Frances T Lee; Dina Elaraj
Journal:  Surg Clin North Am       Date:  2019-08       Impact factor: 2.741

7.  Aldosterone excess impairs first phase insulin secretion in primary aldosteronism.

Authors:  Evelyn Fischer; Christian Adolf; Anna Pallauf; Cornelia Then; Martin Bidlingmaier; Felix Beuschlein; Jochen Seissler; Martin Reincke
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

Review 8.  A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function.

Authors:  John M C Connell; Scott M MacKenzie; E Marie Freel; Robert Fraser; Eleanor Davies
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

9.  Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants.

Authors:  V Ronconi; F Turchi; S Rilli; D Di Mattia; L Agostinelli; M Boscaro; G Giacchetti
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-05-29       Impact factor: 4.222

Review 10.  Effects of aldosterone on insulin sensitivity and secretion.

Authors:  James M Luther
Journal:  Steroids       Date:  2014-09-04       Impact factor: 2.668

View more
  2 in total

Review 1.  Impact of Primary Aldosteronism in Resistant Hypertension.

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Dimitrios Patoulias; Alexandra Katsimardou; Michael Doumas
Journal:  Curr Hypertens Rep       Date:  2022-04-21       Impact factor: 4.592

2.  Differences in Glycemic Abnormalities Between Primary Aldosteronism and Essential Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Worapaka Manosroi; Pichitchai Atthakomol; Pittaporn Wattanawitawas; Supawan Buranapin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-31       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.